Secondary outcomes included changes in body composition, glucose metabolism indicators, lipid metabolism parameters, sex hormone levels, endometrial thickness, ovarian volume, menstrual cycle, and scores on the validated Chinese version of the Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ). This evidence concerns the gene PLXNA3 and polycystic ovary syndrome.